Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Advanced Oncotherapy says development of LIGHT system on track

Advanced Oncotherapy has made “significant advancements” in the technological development and manufacture of its LIGHT system
Advanced Oncotherapy
Progress at the Harley Street site also remains on track

Advanced Oncotherapy (LON:AVO) said it remains on track to deliver its first LIGHT system for treating superficial tumours by the third quarter of 2018.

The developer of next-generation proton therapy systems for cancer treatment said it has made “significant advancements” in the manufacture of the LIGHT system following successful integration and testing of the first Side Coupled Drift Tube Linac (SCDTL) with the Radiofrequency Quadrupole (RFQ) and proton source.

Lower power testing of individual accelerating SCDTL units met expectations and the company said the results “provide confidence that the units are now capable of accelerating a proton beam to 25MeV through the SCDTL”. 

“We are very confident that SCDTLs will work properly, also because an identical system is working up to 35MeV in the ENEA laboratory at Frascati, Italy,” said professor Ugo Amaldi, president of the TERA Foundation and member of company's medical advisory board.

“For the Couple Cavity Linac (CCL) modules, we are also confident since one of them has been successfully built and tested by the TERA Foundation and accelerated protons from 62 to 73MeV."

The group also reported “good progress” in the creation of the Patient Positioning System (PPS), which ensures the patient is prepared for the dose sparing proton treatments produced by the LIGHT system.

The Diagnostic Quality CT scanner used in the treatment room to image patients in a seated position has been manufactured and a real-time X-ray verification for continuous imaging of moving tumours has also been developed.

The overall connectivity from the PPS and the LIGHT system accelerating units has been established and successfully evaluated with system function emulation tools, the company said.

Progress at the Harley Street site also remains on track with the next stage of sub-structural work progressing well.

"I am very pleased that the technological development of our LIGHT system remains on track and, with protons accelerated through three of the main four accelerating structures, the proton source, RFQ and SCDTL, and the design of the fourth accelerating structure already proven, we are confident that we will have a proton therapy system capable of treating superficial tumours by the end of Q3 next year,” said Advanced Oncotherapy chief executive, Nicolas Serandour.

"As we come to the end of the year I am delighted that we enter 2018 in a strong position, not only through the technological developments achieved to date, but also through the security of longer-term financing now completed and with good progress to report at our flagship Harley Street site."

View full AVO profile View Profile

Advanced Oncotherapy Timeline

Related Articles

laboratory
April 12 2018
Mission is to make stem cell treatments accessible and affordable to as many people as possible
picture of addict
November 15 2017
To build the UK's first £1bn, self-sustainable biotech is the aim for chief executive Clive Dix
couple looking at pregnancy test
November 13 2017
The proceeds from the fundraiser will be used to expand in the People's Republic and will invested in product development

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use